BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced positive topline results from its phase 3 clinical trial of DEXTENZA™ (dexamethasone insert) 0.4 mg, for the treatment of post-surgical ocular inflammation and pain. DEXTENZA is a product candidate administered by a physician as a bioresorbable intracanalicular insert
Category: News
Neue bahnbrechende Studie belegt Vermeidbarkeit von Sehverlust bei Erwachsenen mit Diabetes
NEWBURY, England–(BUSINESS WIRE)–Obwohl die Angst vor Sehverlust doppelt so hoch ist wie die Angst vor anderen häufigen mit Diabetes verbundenen Komplikationen (einschließlich Herzkreislauferkrankungen und Schlaganfall), bespricht ein Viertel der befragten Patienten mit Diabetes das Thema Augenkomplikationen nicht mit medizinischem Fachpersonal, während viele erst ärztlichen Rat suchen, wenn Sehkraftprobleme bereits vorhanden sind.1 Dies sind einige der besorgniserregenden Erkenntnisse aus de
New landmark study reveals adults with diabetes at unnecessary risk of vision loss
NEWBURY, England–(BUSINESS WIRE)–Despite vision loss being feared twice as much as other common complications of diabetes (including cardiovascular disease and stroke) a quarter of people with diabetes surveyed are not discussing eye complications wi…
NSAIDs After Cataract Surgery: Do They Help at All? (CME/CE)
(MedPage Today) — Cochrane review finds no clear impact on visual acuity or quality of life
PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) — This week’s topics include a new tool for predicting cardiovascular event risk, iPads for amblyopia, an antibody for non-small cell lung cancer, and high-dose statins.
Trump Posts Preliminary Plan to Repeal ACA
In a new post on his ‘Great Again’ website, President-elect Donald J. Trump outlined his policies for healthcare reform. Medscape Medical News
‘It Would Be Great If I Was Pushed Out of Business’: What We Heard This Week
(MedPage Today) — Quotable quotes from MedPageToday’s sources
‘You’ll Shoot Your Eye Out’: Eye Injuries Spike in Teens, Young Adults (CME/CE)
(MedPage Today) — Basketball, baseball, and air guns caused nearly half of trauma during 2010-13
New Guidelines for Hydroxychloroquine Visual Screening
With increasing and broader use of hydroxychloroquine, more patients are in need of ongoing screening for retinal toxicity. Medscape Optometry
Researchers start enrolling patients for Phase II gene therapy trial for choroideremia
Following on from a successful world’s first Phase I gene therapy trial for choroideremia, Professor Robert MacLaren and his team at Oxford University and the Oxford Eye Hospital at the John Radcliffe Hospital have started a Phase II trial enrolling 30 patients.
Mediterranean Diet May Protect Against Macular Degeneration
A new cross-sectional study has found that eating a Mediterranean diet may protect against development of age-related macular degeneration. Medscape Medical News
EyeQue Awarded CES 2017 Best of Innovation
NEW YORK & NEWARK, Calif.–(BUSINESS WIRE)–The EyeQue Personal Vision Tracker earned the highest honor for CES 2017- Best of Innovation in the Fitness, Sports and Biotech category.
Paintball Players Should Watch Out for Eye Injuries
Paintball and air guns account for one in 10 sports-related eye injuries and one-quarter of cases with vision impairment, a U.S. study suggests. Reuters Health Information
Glaukos Corporation Announces Third Quarter 2016 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
Tobii Pro Launches Pioneering Eye Tracker and Biometric Software Platform for Behavioral Research
STOCKHOLM–(BUSINESS WIRE)–Tobii Pro (STO:TOBII), the global leader in eye tracking research solutions, continues to push the envelope in eye tracking innovation with the launch of Tobii Pro Spectrum and Tobii Pro Lab, its most advanced eye tracking solutions to date. These research tools – to be exhibited at Neuroscience 2016 (https://www.sfn.org/annual-meeting/neuroscience-2016) in San Diego, Calif. – from November 12-16 – will further expand the scope and richness of what can be achieved in
Castle Biosciences Announces Data Presentation at the Society for Melanoma Research 2016 Congress Demonstrating Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma on patient management decisions. The test uses tumor biology to provide an individual risk of recurrence in cutaneous (skin) melanoma patients. The data were presented in a poster session at the Society for Melanoma Research 2016
Pixium Vision’s Iris II Brings Back Sight to Blind for First Time
Pixium Vision, a company based in Paris, France, has announced that its Iris II bionic vision system has been implanted into the first patient. The Iris II was cleared in Europe back in July of this year and the UK regulatory authority, Medicines & Healthcare products Regulatory Agency (MHRA), gave a green light for a clinical trial [ (Read more...)
Keeping an Eye on Zika: Ocular Findings
Microcephaly is just one component of congenital Zika syndrome, and the ocular findings should not be overlooked, says a Brazilian ophthalmologist, who is now also practicing in the United States. Medscape Ophthalmology
Inotek Pharmaceuticals Corporation Reports Third Quarter 2016 Financial Results and Operational Highlights
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today reported financial results and operational highlights for the quarter ended September 30, 2016.
Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results and Provides Corporate Update
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2016 and provided a general business update. “Following productive discussions with the FDA, we are preparing for the resubmission of our NDA for DEXTENZA™ for post-surgical ocular pain by the end of the year,